T1	intervention 22 33	salidroside
T2	condition 37 108	epirubicin-induced early left ventricular regional systolic dysfunction
T3	total-participants 856 861	Sixty
T4	intervention-participants 1004 1006	30
T5	control 1011 1018	placebo
T6	control-participants 1024 1026	30
T10	outcome 1323 1345	decline of the SR peak
T16	outcome 1507 1537	cumulative doses of epirubicin
T12	iv-cont-mean 1460 1464	1.35
T21	iv-cont-sd 1467 1471	0.36
T13	cv-cont-mean 1475 1479	1.42
T22	cv-cont-sd 1482 1493	0.49/second
T14	iv-cont-mean 1674 1678	1.67
T17	iv-cont-sd 1681 1685	0.43
T15	cv-cont-mean 1689 1693	1.32
T23	cv-cont-sd 1696 1707	0.53/second
T18	iv-cont-mean 1734 1738	1.68
T19	iv-cont-sd 1741 1745	0.29
T20	cv-cont-mean 1749 1753	1.40
T24	cv-cont-sd 1756 1767	0.23/second
T11	outcome 1816 1844	plasma concentrations of ROS
